Latest News and Updates | Cantargia

* (R) = Regulatory press releases

Jun 26, 2018

(R) Cantargia announces pre-clinical results showing positive effects of CAN04 combined with approved cancer therapies

Jun 26, 2018

(R) Cantargia obtains two new granted patents in USA for antibody based cancer therapy against IL1RAP

Jun 19, 2018

(R) Cantargia’s immuno-oncology antibody CAN04 has obtained the INN nidanilimab by WHO

Jun 1, 2018

(R) Annual General Meeting in Cantargia AB (publ)

May 21, 2018

(R) Cantargia receives Notice of Allowance from USPTO for the antibody CAN03

May 16, 2018

(R) Cantargia’s immuno-oncology project CAN04 shows promise in additional cancer forms

May 15, 2018

(R) Cantargia publishes interim report for first quarter 2018

May 4, 2018

(R) Cantargia’s European patents for both leukemia and solid tumours remain valid after appeal period ends

May 3, 2018

(R) Cantargia receives patent approval in Canada and broadens protection with respect to hematological cancer

Apr 16, 2018

(R) Cantargia presents anti-metastatic effect of IL1RAP blocking antibody at AACR

<< Newer press releases Older press releases >>

Interview with CEO Hilde H. Steineger - 2025-10-24

Redeye

Interview with CEO Hilde H. Steineger - 2025-10-07

BioStock

Interview with CSO David Liberg about new nadunolimab data in pancreatic cancer presented at AACR Pancreas Conference (In Swedish) - 2025-10-01

Redeye

Interview with Damian Marron about Otsuka Pharmaceutical's acquisition of CAN10 - 2025-07-17

BioStock

Interview with Damian Marron regarding the acquisition of CAN10 IL1RAP immunology program by Otsuka Pharmaceutical - 2025-07-15

Redeye

Cantargia Q1 2025 interview with Interim CEO Damian Marron - 2025-05-14

Redeye

Redeye interviews Interim CEO Damian Marron - 2025-02-07

Redeye